Maternal screening in Pregnancy (Double & quadruple marker)

1Copyright © 2014 Well Woman Clinic. All rights reserved.
Maternal Serum Screening:
Advancements
Dr Nupur Gupta
Department of Obstetrics &
Gynecology

What is a screening test?
 These tests DO NOT diagnose a problem; they only signal that
further testing should be done.
 As diagnostic tests tend to be more expensive and have a degree of
risk; screening tests are quick and easy to do.
 Screening tests have a greater chance of being wrong; there are
“false-positive” (test indicates the baby has the condition when the
baby really does not) and “false-negatives” (baby has the condition
but the test indicates they do not).

 Most babies are born healthy
 About 4 in 100 will be born with a birth defect
 Type of tests: SCREENING & DIAGNOSTIC
 Genetic Counseling
Introduction to Prenatal Screening

What is Maternal Serum Screening?
 Measurement of proteins produced by fetus or placenta
 Results are calculated relative to population standards
(MoMs)
 Screening tests do not look only at results from the
blood test
 They compare a number of different factors (including
age, ethnicity, results from blood tests, etc...) and then
estimate what are a person’s chances of having an
abnormality

 It is a prenatal screening test
 Offered in first (9 to 13+6 weeks) and second
trimester (14 to 22 weeks)
 It gives an estimate of the risk but doesn’t give a
definitive diagnosis
What is this test?

7Copyright © 2014 Well Woman Clinic. All rights reserved. 7
What is Fetal Aneuploidy?
Aneuploidy is having one or more extra or
missing chromosomes, leading to an
unbalanced chromosome number in a cell

 FIRST TRIMESTER SCREEN
 TRIPLE SCREEN
 QUADRUPLE SCREEN
 PENTA SCREEN
 INTEGRATED SCREENING
 SEQUENTIAL SCREENING
SINGLE SCREENING TESTS
COMBINED FIRST & SECOND
TRIMESTER SCREENING
TYPES OF SCREENING

 To detect the risk of having a baby with
chromosomal abnormality
 Risk of developing early onset preeclampsia
Why maternal serum screen?

Why Maternal Serum Screen ?
 Provides a non-invasive method to identify pregnancies at risk
for birth defects rather than performing Chorionic Villous
Sampling (CVS) or Amniocentesis in every case
 Fewer invasive procedures will be required to identify an
aneuploid fetus in patients who have screening
 Individual patient risk is affected by parental age,
medical/pregnancy history, family history of hereditary
disease, mental retardation, or birth defects

All women; choice depends upon
Desire for information before delivery
Prior obstetric history
Family history
Number of foetuses
Availability of reliable NT measurement
Cost of screening
Options for pregnancy care or termination for an
abnormal diagnostic test result
Who should be offered screening
for aneuploidy?

 Down’s syndrome
 Edward’s syndrome
 Patau syndrome
 Down’s syndrome
 Edward’s syndrome
 Neural tube defects
First Trimester Second Trimester
What conditions do these tests look for?

Down Syndrome - Trisomy 21
 Most common chromosomal abnormality 1/800 births
 Congenital and genetic, rarely inherited
 Over 350,000 affected patients in US

Down Syndrome - Trisomy 21
 JLH Down first described it in 1866
 “Observations on an ethnic classification of idiots”
– Average life expectancy 30 years
– Characteristic phenotype
– Learning disability (IQ 20-60)
– Developmental delay
– Delayed puberty / Early menopause
 Major Causes of Morbidity & Mortality
– > 50% visual or hearing impairment
– 30-50% minor to severe heart defects
– 10-20% intestinal malformations
 Others: leukemia-thyroid disease-presenile dementia….

All Live Births
Maternal Age
35 y
87% live births
are to women
< 35 y
#LiveBirths

Down Syndrome Births
35 y
Maternal Age
#DSCases
55% DS cases
occur in women
< 35y

Edwards syndrome – Trisomy 18
 John H. Edwards, first described in 1960
 Most common trisomy after Down
Syndrome
 More common in girls
 The rate of occurrence for Edwards
Syndrome is 1:3000 conceptions and
1:6000 live births
 50% of those diagnosed prenatally with
the condition will not survive the
prenatal period

PATAU SYNDROME
 1 in 10,000 births
 It is a chromosomal condition associated with severe
intellectual disability and physical abnormalities in many
parts of the body
 They have heart defects, brain or spinal cord
abnormalities, microphthalmia, extra fingers or toes, cleft
lip with or without cleft palate and weak muscle tone
(hypotonia)
 Infants usually die within first few days or weeks of life
 Ony 5 to 10% survive past one year

Neural Tube Defects - NTD
 1/1000 live births
 Are birth defects of the brain & spinal cord
 The two most common are spina bifida & anencephaly
 75% affected fetuses miscarry or are stillborn
 95% have no family history
Maternal risk factors:
 Diabetes, anticonvulsants, obesity, low folic acid status

To obtain a complete report…
Patient’s date of birth (not chronological age)
Specimen collection date
Gestational age (Ultrasound report)
Weight at the time of sample collection
 Race
Insulin-dependent diabetes status prior to the pregnancy
Whether this is a repeat sample
Number of fetuses
History of NTD

MORE conditions ………

 Blood tests
 Ultrasound
SCREENING TESTS (Noninvasive)

Role of Ultrasound: Soft markers
 First trimester increased NT: congenital heart &
abdominal wall defects, diaphragmatic hernia
 Second trimester scan detects only 50 to 60% of
Down’s syndrome fetuses
 Third trimester followup: isolated renal pelvis
dilatation, echogenic bowel, or shortened humerus
or femur

 When there is a family history of a particular
condition
 Screening tests show an increased risk of a particular
condition
 Fetal anomaly scan is abnormal
 A woman more than 37 years who does not choose
to have screening
Diagnostic Tests: Amniocentensis/
Chorionic villous sampling

ACOG Recommendations (2007)
 All pregnancies have baseline risk of major malformations and
congenital disorders: approx 3% of newborns have congenital
malformation
 Ideally, all women should be offered aneuploidy screening
before 20 weeks of gestation, regardless of age
 The goal is to offer screening tests with high detection rates
and low false-positive rates

 PAPP A, Free Beta HCG
 Nuchal Translucency
 Maternal age, weight & gestation
First Trimester (11 to 13+6 weeks)

 It is the collection of fluid under the skin at the
back of baby's neck.
 The amount of fluid is measured during a nuchal
translucency (NT) ultrasound scan
What is Nuchal Translucency (NT)?

 Gestational age: 11 to 13+6weeks
 Fetal CRL: 45 to 84 mm
When should NT be measured?

 First trimester Combined
(PAPP-A + Free beta HCG + NT)
 First trimester Triple Combined
(PAPP-A + Free beta HCG + NT + AFP)
 First Trimester Quad Combined
(PAPP-A + Free beta HCG + NT + PlGF +AFP)
 Triple marker
(Free beta HCG + AFP + uE3)
 Quadruple marker
(Free beta HCG + AFP + uE3 +
Inhibin A)
First Trimester Second Trimester
Different models for Prenatal Screening

 Protein produced in the baby’s liver during the
second trimester of pregnancy.
 The levels of AFP generally increase in the
pregnancy & in Open Neural Tube Defects, such as
spina bifida, levels are very high
 AFP levels tend to be lower than average in babies
who have Down syndrome or trisomy 18.
Maternal Serum Alpha Fetoprotein
(MSAFP)

 It is produced by the placenta and crosses into mom’s
blood stream
 Its levels rise about mid-pregnancy and then begin to
decline
 Babies with Down syndrome tend to have higher than
average levels of hCG
 Babies with trisomy 18 tend to have lower than
average levels of hCG
hCG or Human Chorionic Gonadotropin

 It is made by both the baby’s liver and the placenta
 Levels of this protein rise throughout the pregnancy
 Babies with Down syndrome or trisomy 18 tend to
have lower levels of uE3
UE3 or Unconjugated Estriol

It comes from the placenta
Levels of this protein in mom’s blood remain
relatively constant through the 15th-18th week of
pregnancy
Babies with Down syndrome tend to have higher
than average levels of inhibin-A and
Babies with trisomy 18 tend to have lower than
average levels of inhibin-A
Inhibin-A or dimeric inhibin-A

Huang et al 2014 Prenat Diag

First Tri Quad is better than 2nd Tri Triple

 Started in the 1970’s when it was found that fetal neural tube
defects were associated with increase in maternal MSAFP
 Such measurements were offered to pregnant woman for
screening purposes
 It was also noted that MSAFP tended to be low in fetal down’s
syndrome.
 With a cut off of 2.0 multiples of median[MOM] 85% of NTD’s
would be screened in & with a threshold of 0.5 MOM approx
33% of DS fetus would be screened
Second trimester biochemical screening

Quad Screen: Analytes
15 20
Gestational Age (weeks)
AFP
UE3
HCG
Screening Window
DIA

Triple Vs Quad Screen
79
72
68
70
72
74
76
78
80
Higher
Detection Rates
Fewer
Invasive
Procedures
Triple
Quad
Triple Quad
Source: Adapted from Wald, et. al. NEJM, 341:7, 461-467
Source: Adapted from Palomaki, et. al. Clin Chem.
2004; 50:1804-1808.
Down Syndrome Sensitivity in 2nd
Trimester
9.9
14.6
0
2
4
6
8
10
12
14
16
% of Women Requiring Amnio or CVS for a DR of
85%
Quad has higher detection rates & fewer invasive procedures

Adding markers improved sensitivity….

Free beta HCG improved senstivity…

Free beta HCG showed better results…..

If Positive Screening Test
 Offer diagnostic testing (Invasive CVS or
amniocentensis)
 NIPT (cell free DNA)
 Advanced Level II scan
 Genetic counseling should be offered if
increased NT or cystic hygroma
 Fetal Echo at 24 weeks
Women with negative screening should not be offered
a repeat screening test

Preeclampsia Screening

Prevalence of Preeclampsia

Long-term effects of Preeclampsia

PlGF is the most discriminating biochemical
marker for preeclampsia in first trimester

Biomarker screening & preeclampsia risk
Poon et al 2014 Prenat Diag

Dissociation Enhanced Lanthanide
Fluorescence Immunoassay
Fetal Medicine Foundation (FMF)
Algorithm supports DELFIA platform

Conclusion
 Future is Prenatal Testing
 In First Trimester
 Prevention of morbidity

THANK YOU

Maternal screening in Pregnancy (Double & quadruple marker)

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ähnlich wie Maternal screening in Pregnancy (Double & quadruple marker)

Ähnlich wie Maternal screening in Pregnancy (Double & quadruple marker) (20)

Mehr von Dr Nupur Gupta High Risk Obstetrician

Mehr von Dr Nupur Gupta High Risk Obstetrician (20)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

Maternal screening in Pregnancy (Double & quadruple marker)